Article Versions Notes

Weesner JA, Annunziata I, Yang T, Acosta W, Gomero E, Hu H, van de Vlekkert D, Ayala J, Qiu X, Fremuth LE, et al. Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis. Cells. 2022; 11(16):2579. https://doi.org/10.3390/cells11162579

Weesner, Jason Andrew, Ida Annunziata, Tianhong Yang, Walter Acosta, Elida Gomero, Huimin Hu, Diantha van de Vlekkert, Jorge Ayala, Xiaohui Qiu, Leigh Ellen Fremuth, and et al. 2022. "Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis" Cells 11, no. 16: 2579. https://doi.org/10.3390/cells11162579

Weesner, J. A., Annunziata, I., Yang, T., Acosta, W., Gomero, E., Hu, H., van de Vlekkert, D., Ayala, J., Qiu, X., Fremuth, L. E., Radin, D. N., Cramer, C. L., & d’Azzo, A. (2022). Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis. Cells, 11(16), 2579. https://doi.org/10.3390/cells11162579